Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma

Hepatology

Volumn 62, Issue 4, 2015, Pages 1145-1159

  Nie, Huizhen ^a   Li, Jun ^a   Yang, Xiao Mei ^a   Cao, Qing Zhen ^a   Feng, Ming Xuan ^a   Xue, Feng ^a   Wei, Lin ^a   Qin, Wenxin ^a   Gu, Jianren ^a   Xia, Qiang ^a   Zhang, Zhi Gang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; LACTIC ACID; MICRORNA; MICRORNA 338 3P; MINERALOCORTICOID RECEPTOR; PYRUVATE KINASE; PYRUVATE KINASE LIVER AND RED BLOOD CELLS; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MIRN338 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CELL CYCLE; CELL PROLIFERATION; CHROMOSOME DELETION; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; GLYCOLYSIS; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; DISEASE COURSE; FEMALE; GENETICS; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; GLYCOLYSIS; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PYRUVATE KINASE; RECEPTORS, MINERALOCORTICOID; TUMOR CELLS, CULTURED;

EID: 84942551152     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27940     Document Type: Article

References (37)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
2. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-270.
3. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13:472-482.
4. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
5. Hitosugi T, Chen J. Post-translational modifications and the Warburg effect. Oncogene 2014;33:4279-4285.
6. Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol 2010;6:515-525.
7. Gallagher EJ, Leroith D. Is growth hormone resistance/igf-1 reduction good for you? Cell Metab 2011;13:355-356.
8. Wu ZS, Yang K, Wan Y, Qian PX, Perry JK, Chiesa J, et al. Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma. J Clin Endocrinol Metab 2011;96:E1619-E1629.
9. Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 2011;7:11-24.
10. Leduc F, Brauch H, Hajj C, Dobrovic A, Kaye F, Gazdar A, et al. Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers. Am J Hum Genet 1989;44:282-287.
11. Drabkin H, Kao FT, Hartz J, Hart I, Gazdar A, Weinberger C, et al. Localization of human ERBA2 to the 3p22-3p24.1 region of chromosome 3 and variable deletion in small cell lung cancer. Proc Natl Acad Sci USA 1988;85:9258-9262.
12. Chen LC, Matsumura K, Deng G, Kurisu W, Ljung BM, Lerman MI, et al. Deletion of two separate regions on chromosome 3p in breast cancers. Cancer Res 1994;54:3021-3024.
13. Markowitz S, Haut M, Stellato T, Gerbic C, Molkentin K. Expression of the erbA-b class of thyroid hormone receptors is selectively lost in human colon carcinoma. J Clin Invest 1989;84:1683-1687.
14. Puzianowska-Kuznicka M, Nauman A, Madej A, Tanski Z, Cheng S, Nauman J. Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma. Cancer Lett 2000;155:145-152.
15. Enge M, Bjarnegård M, Gerhardt H, Gustafsson E, Kalén M, Asker N, et al. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 2002;21:4307-4316.
16. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, et al. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 2009;49:1563-1570.
17. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin 2013;63:11-30.
18. Wang K, Lim HY, Shi S, Lee J, Deng S, Xie T, et al. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology 2013;58:706-717.
19. Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ, et al. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res 2009;39:786-794.
20. Lee HA, Lee DY, Cho HM, Kim SY, Iwasaki Y, Kim IK. Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension. Circ Res 2013;112:1004-1012.
21. Ziera T, Irlbacher H, Fromm A, Latouche C, Krug SM, Fromm M, et al. Cnksr3 is a direct mineralocorticoid receptor target gene and plays a key role in the regulation of the epithelial sodium channel. FASEB J 2009;23:3936-3946.
22. Horisberger JD, Rossier BC. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension 1992;19:221-227.
23. Marzolla V, Armani A, Feraco A, De Martino MU, Fabbri A, Rosano G, et al. Mineralocorticoid receptor in adipocytes and macrophages: a promising target to fight metabolic syndrome. Steroids 2014;91:46-53.
24. Meinel S, Gekle M, Grossmann C. Mineralocorticoid receptor signaling: crosstalk with membrane receptors and other modulators. Steroids 2014;91:3-10.
25. Grossmann C, Wuttke M, Ruhs S, Seiferth A, Mildenberger S, Rabe S, et al. Mineralocorticoid receptor inhibits CREB signaling by calcineurin activation. FASEB J 2010;24:2010-2019.
26. Tiberio L, Nascimbeni R, Villanacci V, Casella C, Fra A, Vezzoli V, et al. The decrease of mineralcorticoid receptor drives angiogenic pathways in colorectal cancer. PLoS One 2013;8:e59410.
27. Jeong Y, Xie Y, Xiao G, Behrens C, Girard L, Wistuba II, et al. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med 2010;7:e1000378.
28. Huang XH, Chen JS, Wang Q, Chen XL, Wen L, Chen LZ, et al. miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol 2011;225:463-472.
29. Sun J, Feng X, Gao S, Xiao Z. microRNA-338-3p functions as a tumor suppressor in human non-small-cell lung carcinoma and targets Ras-related protein 14. Mol Med Rep 2015;11:1400-1406.
30. Chen X, Pan M, Han L, Lu H, Hao X, Dong Q. miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett 2013;587:3729-3737.
31. Li P, Chen X, Su L, Li C, Zhi Q, Yu B, et al. Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One 2013;8:e66782.
32. Szyniarowski P, Corcelle-Termeau E, Farkas T, Høyer-Hansen M, Nylandsted J, Kallunki T, et al. A comprehensive siRNA screen for kinases that suppress macroautophagy in optimal growth conditions. Autophagy 2011;7:892-903.
33. Jacovetti C, Abderrahmani A, Parnaud G, Jonas JC, Peyot ML, Cornu M, et al. MicroRNAs contribute to compensatory β cell expansion during pregnancy and obesity. J Clin Invest 2012;122:3541-3551.
34. Nielsen S, Åkerström T, Rinnov A, Yfanti C, Scheele C, Pedersen BK, et al. The miRNA plasma signature in response to acute aerobic exercise and endurance training. PLoS One 2014;9:e87308.
35. Ahmad N, Kumar R. Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett 2011;300:1-9.
36. Sisci D, Surmacz E. Crosstalk between IGF signaling and steroid hormone receptors in breast cancer. Curr Pharm Des 2007;13:705-717.
37. Chaudhri RA, Schwartz N, Elbaradie K, Schwartz Z, Boyan BD. Role of ERα36 in membrane-associated signaling by estrogen. Steroids 2014;81:74-80.